STOCK TITAN

Jazz Pharma (NASDAQ: JAZZ) director plans $858K stock sale

(Neutral)
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Jazz Pharmaceuticals plc (JAZZ) is the issuer for which Norbert G. Riedel, identified as a director, has filed a notice of proposed sale of common stock under Rule 144. The notice covers 3,507 shares of common stock, to be sold through E*TRADE Financial Corporation on or after August 31, 2026, with an indicated aggregate market value of $857,602.00. The shares derive from restricted stock vesting dated August 28, 2026 and are described as acquired from the issuer as compensation.

Positive

  • None.

Negative

  • None.
Shares to be sold 3,507 shares of common stock Proposed sale under Rule 144
Aggregate market value $857,602.00 Value of 3,507 common shares proposed to be sold
CUSIP 64914577 Identifier for Jazz Pharmaceuticals plc common stock listed in the notice
Proposed sale date 08/31/2026 Date listed for proposed sale of the 3,507 shares
Acquisition (vesting) date 08/28/2026 Restricted stock vesting date for the shares to be sold
Rule 144 regulatory
"See the definition of "person" in paragraph (a) of Rule 144."
Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.
restricted stock vesting financial
"COMMON | 08/28/2026 | RESTRICTED STOCK VESTING | ISSUER"
Restricted stock vesting is the timetable and conditions under which shares granted to employees or insiders become fully owned and can be sold, typically requiring continued work or meeting performance goals. It matters to investors because large blocks of shares can become tradable at once, which can change share supply and price, and because vesting aligns insiders’ incentives with the company’s long‑term performance—think of it like a timed unlock that both rewards and locks in key people.
power of attorney regulatory
"Signature | /s/Paz Dizon by power of attorney for Norbert G. Riedel"
A power of attorney is a legal document that allows one person to make decisions and act on behalf of another person, often in financial or legal matters. It’s like giving someone a trusted helper or agent the authority to handle important tasks if you are unable to do so yourself. This matters to investors because it can impact how their assets are managed or transferred if they become unable to oversee their affairs.

FAQ

What does the Form 144 filing disclose for JAZZ?

It discloses that director Norbert G. Riedel has filed a notice of intent to sell 3,507 shares of Jazz Pharmaceuticals plc common stock under Rule 144, with an indicated aggregate market value of $857,602.00, through E*TRADE Financial Corporation.

How many JAZZ shares are covered by this Form 144 notice?

The notice covers 3,507 shares of Jazz Pharmaceuticals plc common stock proposed to be sold under Rule 144.

What is the aggregate market value of the JAZZ shares in this Form 144?

The filing lists an aggregate market value of $857,602.00 for the 3,507 shares of Jazz Pharmaceuticals plc common stock covered by the notice.

When are the JAZZ shares expected to be sold under this Form 144?

The filing indicates a proposed sale date of August 31, 2026 for the 3,507 shares of Jazz Pharmaceuticals plc common stock.

How were the JAZZ shares in this Form 144 acquired?

The shares are described as restricted stock vesting on August 28, 2026 and are noted as acquired from the issuer, Jazz Pharmaceuticals plc, as compensation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature